Acquisition

Biomapas acquires Pinnaxis to expand drug-safety technology services

What's the news? BiomapasDealroom has a profile for this one. Try Dealroom →, a European contract research organisation (CRO) providing clinical, regulatory and drug-safety services, announced on 6 October 2026 that it has acquired Pinnaxis, a US-based pharmacovigilance technology specialist. The deal adds more than 100 technical experts plus proprietary tools for safety-data migration, reporting and case-intake automation to Biomapas.

Why it matters: Pharmacovigilance is the science of monitoring medicines for side effects once they reach patients — a regulatory requirement for every marketed drug. Pinnaxis brings deep engineering and configuration expertise on the major safety platforms (Veeva Safety Vault, Oracle Argus and ArisGlobal) and will lead Biomapas' new Consulting & Digital business unit, accelerating the company's use of automation and AI in routine safety work. The acquisition also expands Biomapas' US presence through Pinnaxis' New Jersey office and client base, supporting its North American growth plans.

Read more: Contract Pharma, 6 October 2026

More top stories